Skip to main content

Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population

Publication ,  Journal Article
Wittbrodt, ET; Eudicone, JM; Bell, KF; Enhoffer, DM; Latham, K; Green, JB
Published in: The American journal of managed care
April 1, 2018

OBJECTIVES: Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features such as enrollment criteria present a challenge when trying to assess the applicability of these studies to real-world T2D populations. This study evaluated the proportions of US adults with T2D who met the eligibility criteria for each of the 4 sodium-glucose cotransporter-2 (SGLT2) inhibitor CVOTs. STUDY DESIGN: A cross-sectional retrospective study was conducted using data from the National Health and Nutrition Examination Survey (NHANES) and published patient eligibility criteria for completed or ongoing SGLT2 inhibitor CVOTs. METHODS: Data on T2D diagnosis and other relevant clinical and demographic characteristics were extracted from the NHANES (2009-2010 and 2011-2012). Weighted analysis of these data was used to estimate the percentage of US adults with T2D who met the eligibility criteria for the CANVAS program (CANagliflozin cardioVascular Assessment Study) (canagliflozin; NCT01032629, NCT01989754), and the DECLARE-TIMI 58 (dapagliflozin; NCT01730534), EMPA-REG OUTCOME (empagliflozin; NCT01131676), and VERTIS-CV (ertugliflozin; NCT01986881) trials. RESULTS: The weighted analysis identified a population of 23,941,512 US adults from data on key inclusion criteria and information indicating a diagnosis of T2D. Of these, 4.1% met the criteria for EMPA-REG OUTCOME, 4.8% for VERTIS-CV, 8.8% for the CANVAS program, and 39.8% for the DECLARE-TIMI 58 trial. CONCLUSIONS: There were considerable differences in the proportions of US adults with T2D who met the eligibility criteria for these studies.The DECLARE-TIMI 58 trial criteria were the most generalizable to the US T2D population.

Duke Scholars

Published In

The American journal of managed care

EISSN

1936-2692

Publication Date

April 1, 2018

Volume

24

Issue

8

Start / End Page

S138 / S145

Related Subject Headings

  • Health Policy & Services
  • 4203 Health services and systems
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wittbrodt, E. T., Eudicone, J. M., Bell, K. F., Enhoffer, D. M., Latham, K., & Green, J. B. (2018). Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. The American Journal of Managed Care, 24(8), S138–S145.
Wittbrodt, E. T., J. M. Eudicone, K. F. Bell, D. M. Enhoffer, K. Latham, and J. B. Green. “Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.” The American Journal of Managed Care 24, no. 8 (April 1, 2018): S138–45.
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. The American journal of managed care. 2018 Apr 1;24(8):S138–45.
Wittbrodt, E. T., et al. “Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.” The American Journal of Managed Care, vol. 24, no. 8, Apr. 2018, pp. S138–45.
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. The American journal of managed care. 2018 Apr 1;24(8):S138–S145.

Published In

The American journal of managed care

EISSN

1936-2692

Publication Date

April 1, 2018

Volume

24

Issue

8

Start / End Page

S138 / S145

Related Subject Headings

  • Health Policy & Services
  • 4203 Health services and systems
  • 1117 Public Health and Health Services